Loading...
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA convened a panel of experts on Friday to examine the accuracy of point-of-care tests to measure international normalized ratio (INR) in patients taking warfarin, the Wall Street Journal reports.
The agency says such tests have performed poorly in thousands of patients since their approval, with potentially false readings linked to 18 deaths in 2014 and 2015.
Two such tests, INRatio and INRatio2, were withdrawn from the market in 2014 over concerns that they gave faulty readings. INRatio has recently received much attention over its use in the ROCKET AF trial, which led to approval of the anticoagulant rivaroxaban (Xarelto). Critics assert that in ROCKET AF, falsely low INR readings with INRatio would have prompted higher warfarin doses — resulting in higher bleeding risks with the drug and thus making rivaroxaban seem relatively safer. The researchers reanalyzed their data, however, and concluded that the test did not significantly affect the trial's primary outcomes.
Comment
LINK(S):
Wall Street Journal story (Subscription required)
Background: Physician's First Watch recent coverage of ROCKET AF controversy (Free)